Overview

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Status:
RECRUITING

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Collaborator:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin